Literature DB >> 9247408

Case-control study of neuroleptic malignant syndrome.

P Sachdev1, C Mason, D Hadzi-Pavlovic.   

Abstract

OBJECTIVE: The authors performed a case-control study of neuroleptic malignant syndrome to identify potential risk factors.
METHOD: Twenty-five patients with neuroleptic malignant syndrome were matched with 50 comparison subjects on age, sex, primary psychiatric diagnosis, and time of admission to the hospital. The records of all subjects were reviewed independently by two researchers for information on postulated risk factors. Exploratory direct comparisons of the two groups were followed by a conditional logistic regression analysis.
RESULTS: Patients with neuroleptic malignant syndrome were more likely to be agitated or dehydrated before the development of neuroleptic malignant syndrome, often needed restraint or seclusion, and received larger doses of neuroleptics soon after hospitalization. Previous treatment with ECT increased vulnerability.
CONCLUSIONS: The prevalence of neuroleptic malignant syndrome may be reduced by avoiding large doses of neuroleptics over short periods in the management of acute psychosis and by paying adequate attention to the patient's hydration and electrolyte status.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247408     DOI: 10.1176/ajp.154.8.1156

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  9 in total

1.  Neuroleptic malignant syndrome with metoclopramide overdose coexisting with Clostridium difficile diarrhea.

Authors:  Azhar Supariwala; Gunjan Kant; Raymonde E Jean
Journal:  Intensive Care Med       Date:  2011-06-18       Impact factor: 17.440

2.  NEUROLEPTIC MALIGNANT SYNDROME.

Authors:  S K Mayanil; U R Tampi
Journal:  Med J Armed Forces India       Date:  2017-06-10

3.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12

4.  Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.

Authors:  Daiji Kato; Chiaki Kawanishi; Ikuko Kishida; Taku Furuno; Kyoko Suzuki; Hideki Onishi; Yoshio Hirayasu
Journal:  Eur J Clin Pharmacol       Date:  2007-08-14       Impact factor: 2.953

Review 5.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.

Authors:  Enasio Morris; Digby Green; Andis Graudins
Journal:  J Med Toxicol       Date:  2009-03

7.  Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients.

Authors:  Pradyot Sarkar; Chandrashekhar Natarajan; Neeta Gode
Journal:  Indian J Psychiatry       Date:  2009 Jul-Sep       Impact factor: 1.759

8.  Afebrile Neuroleptic Malignant Syndrome associated with Fluphenazine decanoate: A case report.

Authors:  Marzieh Assareh; Laleh Koohi Habibi
Journal:  Iran J Psychiatry       Date:  2010

Review 9.  Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report.

Authors:  Julie Langan; Daniel Martin; Polash Shajahan; Daniel J Smith
Journal:  BMC Psychiatry       Date:  2012-11-29       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.